RxDoctor Payments Data

Alan Kenney, MD

Family Medicine · Mesquite, TXNPI 1922033612

Payments from drug & device makers

$19,211in general payments, 2019–2025

Across 1,118 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • GSK$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Pfizer$1K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$1,2006%
  • Food & beverage$17,98094%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim109$1,914
Novo Nordisk115$1,885
AstraZeneca98$1,758
GSK85$1,511
Biohaven Pharmaceuticals, Inc.10$1,268
Pfizer88$1,194
Lilly USA, LLC87$1,106
Amgen(2 entities)55$908
Bayer48$853
AbbVie(2 entities)56$815
Merck61$747
Amarin Pharma, Inc.37$558
Johnson & Johnson40$547
Dexcom, Inc.17$503
Esperion Therapeutics, Inc.28$452
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$312
Idorsia Pharmaceuticals US Inc16$309
Sanofi-aventis U.S. LLC14$224
Teva Pharmaceuticals USA, Inc.11$211
Eisai Inc.7$144
Ironwood Pharmaceuticals, Inc7$123
Novartis6$110
Exact Sciences6$104
Kowa Pharmaceuticals America, Inc.6$103
Astellas Pharma US Inc6$96
Scilex Pharmaceuticals Inc.4$86
Avvisto Therapeutics, LLC5$81
Sanofi Pasteur Inc.5$80
Biohaven Pharmaceutical Holding Company Ltd.5$76
Abbott4$72
Optinose US, Inc.3$71
Sunovion Pharmaceuticals Inc.4$69
Phathom Pharmaceuticals, Inc.4$68
Antares Pharma, Inc.4$64
Genentech USA, Inc.4$61
Dynavax Technologies Corporation3$52
E.r. Squibb & Sons, L.L.C.3$48
Inspire Medical Systems, Inc.1$43
Intuity Medical Inc3$43
Philips North America LLC3$42
Melinta Therapeutics, LLC3$38
Boston Scientific1$37
Acadia Pharmaceuticals Inc2$37
Xeris Pharmaceuticals, Inc.2$34
Arbor Pharmaceuticals, Inc.2$29
Currax Pharmaceuticals LLC2$27
Takeda Pharmaceuticals U.S.A., Inc.6$25
OPKO Pharmaceuticals, LLC2$25
Edwards Lifesciences1$23
Gilead1$23
Phadia US Inc.1$23
Paratek Pharmaceuticals, Inc.1$19
Renalytix AI, Inc.1$19
Biogen1$17
Stryker1$17
Redhill Biopharma Inc.1$16
Impel Pharmaceuticals Inc.1$16
Otsuka America Pharmaceutical, Inc.1$16
Vertex1$15
Lifescan, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,211 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$47,011
Medicare patients
143
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide89$115,664
OzempicSemaglutide98$98,319
JardianceEmpagliflozin71$86,326
TrulicityDulaglutide63$77,556
RybelsusSemaglutide38$63,253
EliquisApixaban49$48,609
Breztri AerosphereBudesonide/Glycopyr/Formoterol53$47,304
JanuviaSitagliptin Phosphate46$45,043
FarxigaDapagliflozin Propanediol32$43,957
LinzessLinaclotide47$33,408
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog53$31,287
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$25,995
Breo ElliptaFluticasone/Vilanterol18$16,081
SymbicortBudesonide/Formoterol Fumarate45$14,540
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$10,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,106$193,220152 claims
Novo NordiskOzempic, Rybelsus$1,885$161,572136 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$1,758$105,801130 claims
Boehringer IngelheimJardiance, Spiriva Respimat$1,914$96,60491 claims
MerckJanuvia, Lagevrio (Eua)$747$53,67258 claims
PfizerEliquis, Premarin$1,194$51,15961 claims
GSKTrelegy Ellipta, Breo Ellipta$1,511$42,07656 claims
AbbVieLinzess, Synthroid$815$36,79276 claims
NovartisEntresto$110$9,97912 claims
Scilex Pharmaceuticals Inc.Colchicine$86$3,31561 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Mesquite

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →